|
|
|
|
|
|
|
|
|
30.07.26 - 22:09
|
Hercules Capital Reports Second Quarter 2026 Financial Results (Business Wire)
|
|
|
Record 1H 2026 Total New Debt and Equity Commitments of $2.74 Billion, an Increase of 35.6% Year-over-Year
Record 1H 2026 Total Fundings of $1.35 Billion, an Increase of 8.5% Year-over-Year
Record 1H 2026 Total Investment Income of $290.7 Million, an Increase of 13.1% Year-over-Year
Record 1H 2026 Net Investment Income “NII” of $181.0 Million, an Increase of 8.9% Year-over-Year
Record Q2 2026 Total Investment Income of $149.1 Million, an Increase of 8.5% Year-over-Year
Record Q2 2026 NII of $92.9 Million, an Increase of 4.7% Year-over-Year
Q2 2026 NII of $0.50 per Share provides 125% Coverage of the Base Cash Distribution
Conservative Balance Sheet Management with Net GAAP Leverage of 101.8% and Net Regulatory Leverage of 86.4%(1)
Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercules had over $1.0 Billion of Available Liquidity as of the end of Q2 2026
Undistributed Earnings Spillover of $171.7 Million, or $0.92(2) per Ending Shares Outstanding
Approxima...
|
|
|
|
|
28.07.26 - 12:09
|
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026 (Business Wire)
|
|
|
The Total Cash Distribution of $0.47 per Share for the Second Quarter 2026 is Comprised of a $0.40 per Share Base Distribution and $0.07 per Share Supplemental DistributionSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a second quarter 2026 total cash distribution of $0.47 per share. The following shows the key dates of the second quarter 2026 distribution payment:
Record Date
August 11, 2026
Payment Date
August 18, 2026
Hercules' Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% to 100% of the Company's taxable quarterly income or potential a...
|
|
|
24.07.26 - 22:06
|
Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031 (Business Wire)
|
|
|
Notes due 2031 Initially Assigned Ratings of Baa2 by Moody's Investors Service and a BBB- by Fitch Ratings, Inc.SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”).
The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually, will mature on July 24, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a “make whole” premium, if applicable.
The Company expects to use the net proceeds from this offering to (i) repay outstanding unsecured indebtedness and/or secured indebtedness under its existing financing arrangements, (ii) fund investments in accordance with its investment objectives, and (iii) for other general corporate purposes.
Goldman Sachs & Co. LLC, SMBC N...
|
|
|
|
|
|
|
21.07.26 - 22:18
|
Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031 (Business Wire)
|
|
|
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on July 24, 2026.
The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually and will mature on July 24, 2031 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a “make whole” premium, if applicable.
The Company expects to use the net proceeds from this offering to (i) repay outstanding unsecured indebtedness and/or secured indebtedness under its existing financing arrangements, (ii) fund investments in accordance with its investment objectives, and (iii) for other general corporate purp...
|
|
|
|
|
16.07.26 - 12:06
|
Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call (Business Wire)
|
|
|
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2026 financial results conference call for Thursday, July 30, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.
All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of our website at investor.htgc.com. Please visit the website to test your connection before the webcast. Domestic callers can access the conference call toll free by dialing +1 (800) 267-6316. International callers can access the conference call by dialing +1 (203) 518-9783....
|
|
|
|
|
29.06.26 - 14:03
|
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital (GlobeNewswire EN)
|
|
|
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
